Anti-EMR1/ADGRE1 (F4/80) antibody [RM1302],Abcam,AB323648

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are recombinant multiclonals? Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including: - The sensitivity of polyclonal antibodies by recognising multiple epitopes - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production View our range of recombinant multiclonal antibodies .

Host

Rabbit

Reactivity

Human, Mouse, Rat

Application

IP, WB, Flow Cyt, IHC-P

Platform ID

BAB354685285

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-EMR1/ADGRE1 (F4/80) antibody [RM1302]
Cat. No.AB323648
HostRabbit
IsotypeIgG
ReactivityHuman, Mouse, Rat
ApplicationIP, WB, Flow Cyt, IHC-P
ClonalityMulticlonal
Clone NumberRM1302
Concentration0.489 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Orphan receptor involved in cell adhesion and probably in cell-cell interactions specifically involving cells of the immune system. May play a role in regulatory T-cells (Treg) development. See full target information Adgre1 Additional targets ADGRE1,Adgre1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.